Additional file 2: of Integrative omics analyses broaden treatment targets in human cancer

Table S1. Drug classes in DEPO (database of evidence for precision oncology). Table S2. Sensitive druggable mutations in 6570 TCGA tumors. Table S3. Highest level of evidence present per variant for both resistant and sensitive. Table S4. Drugs represented in the GDSC Cell Line Data. Table S5. Cell lines that contain a sensitive mutation in DEPO. Table S6. Mann-Whitney U test of distribution of Ln(IC50) values in cell lines with DEPO sensitive mutations against background distribution for each drug. Table S7. Linear regression statistics for probe-drug pairs. Table S8. TCGA tumors (out of 3121) that are druggable based on two or more variant types (genomic, transcriptomic, proteomic). Table S9. Ten FDA-approved drug classes. Table S10. TCGA tumors that are druggable with one of ten classes of FDA-approved cancer drugs based on two or more variant types (genomic, transcriptomic, proteomic). Table S11. Druggability and demographics. Table S12. Cancer types responsible for the levels of evidence in the cancer type non-specific setting for Fig. 2a. Table S13. Novel druggable mutations clustering with known druggable mutations identified using HotSpot3D, a proximity-based clustering tool. Table S14. RNA-seq data and protein RPPA data for 6366 and 3877 TCGA tumors, respectively. Table S15. Druggable fusions in TCGA samples. Table S16. Evidence to support repurposing of proteogenomic alterations across cancer types. Table S17. Co-occurring druggable mutations. Table S18. Gene expression outlier scores and drug response for all cell lines. Table S19. TCGA tumors (out of 6570) that are druggable based on atleast one variant (genomic, transcriptomic, proteomic). (.xlsx 2.1 MB) (XLSX 2039 kb